Long-term gastrointestinal tolerance of NUTRIOSE®FB in healthy men

Autor: Wilrike Pasman, M.-H. Saniez, Daniel Wils, A. F. M. Kardinaal
Přispěvatelé: TNO Kwaliteit van Leven TNO Voeding
Rok vydání: 2006
Předmět:
Questionnaires
Male
Hunger
Macronutrient
Medicine (miscellaneous)
Gastroenterology
law.invention
Feces
Hydrogen breath test
Randomized controlled trial
Quality of life
Absence of side effects
Food intake
law
Controlled clinical trial
Surveys and Questionnaires
Enzyme activity
Hematological parameters
Food science
Drug tolerability
Nutrition and Dietetics
medicine.diagnostic_test
Feces analysis
Short chain fatty acid
Lactic acid
Double blind procedure
Sitosterol
Dietary fiber
Adaptation
Physiological

Nutriose fb
Clinical trial
Diarrhea
Cholesterol
Cholesterol blood level
Body mass
Breath Tests
Health
Food composition
medicine.symptom
Adult
medicine.medical_specialty
Beta glucosidase
Diet therapy
Fermentation technique
Diet supplementation
Placebo
Colon flora
Maltodextrin
Double-Blind Method
Polysaccharides
Gastrointestinal symptom
Internal medicine
Dextrins
medicine
Humans
Biomedical research
Alpha glucosidase
Drug excretion
Adaptation
Coprosterol
Dose-Response Relationship
Drug

business.industry
Probiotics
Body Weight
Body weight
Satiety
Glucose
Food preference
Fermentation
Quality of Life
Glucidex
Habituation
Caloric intake
Energy Intake
business
PH measurement
Zdroj: European Journal of Clinical Nutrition, 8, 60, 1024-1034
ISSN: 1476-5640
0954-3007
DOI: 10.1038/sj.ejcn.1602418
Popis: Objective: To determine the gastrointestinal (GI) tolerance of NUTRIOSE®FB in men. Design: A randomized, placebo-contro lled, parallel, double-blind study. Setting: The metabolic ward of TNO Quality of Life. Subjects: Forty-eight subjects started the study: 16 men participated in one of the three treatments. Subjects consumed either 22.5 g of pure maltodextrin (Glucidex®6), or 30 or 45 g of the dextrin NUTRIOSE®FB daily for 4-5 weeks. Forty-three subjects completed the study (age: 34.7±8.2 years; BMI 24.9±3.3 kg m2). Measurements: Tolerance of NUTRIOSE®FB was examined with a GI complaints questionnaire; effectiveness on colonic flora was examined by faecal analysis; fermentation by breath hydrogen excretion measurement. Furthermore, the effect on body weight (BW), energy intake and blood parameters were examined in the study. Results: Both doses of NUTRIOSE®FB were very well tolerated and GI complaints hardly differed from the placebo treatment. No diarrhoea was reported due to NUTRIOSE®FB supplementation. In the course of the study, some habituation and adaptation of GI symptoms were found. Fermentation and faecal characteristics (pH and enzyme activity) were significantly positively affected with NUTRIOSE®FB treatment. Body weight in both NUTRIOSE®FB groups remained stable over time, although the placebo-treated group showed a small increase in BW (Δday35-1 0.8±1.0 kg) (P=0.07). However, total food intake and macronutrient composition of the diet remained the same throughout the study. No significant differences were found between the three treatment groups in hunger and satiety scores and food preferences. Conclusions: Long-term supplementation of 30 or 45 g of the dextrin NUTRIOSE®FB per day was well tolerated, and may act as a pre-biotic supplement. © 2006 Nature Publishing Group. All rights reserved.
Databáze: OpenAIRE